Search

Cancer Biotherapy and Radiopharmaceuticals officially retracts the paper entitled, "LncRNA SNHG16 Promotes Proliferation, Migration, and Invasion of Glioma Cells Through Regulating the miR-490/PCBP2 Axis," by Fangen Kong, Yang Yan, Jinfeng Deng, Yaoli Zhu, Yingqin Li, Huiqing Li, and Yiping Wang (Cancer Biother Radiopharm. E-pub ahead of print 23 Jul 2020; doi: 10.1089/cbr.2019.3535) at the authors' request: "We apologized that we have found a serious problem in our paper. In fact, the Western blot experiment in our study was commissioned a third-party company for testing. In present, some peers have found that the company has forged experimental reports. After contacting the company, they were unable to provide the original images. We have checked and confirmed that the authenticity of the data provided by the company is problematic. In view of the problems in this paper, all the authors have discussed and agreed to withdraw the paper." [sic] The journal publisher requested the name of the "third-party company," to which the authors replied: "We apologize for our mistakes. Our so-called "the third party company", after further investigation, is actually not a company but an individual person. Due to the personal reasons, the previous experimental data were lost and the original raw data could not be provided. So we can not guarantee the authenticity of those data provided by that person. Some members are considering to repeat the experiment again, but we have no way to raise enough fund to repeat it. Hence after serious discussion, we decided to withdraw the manuscript.Again we apologize sincerely for your inconvenience." [sic] Submissions from a third party are a violation of the journal's standard protocols and is considered an infraction against the rigorous standards of scientific publishing. The Editor and Publisher of Cancer Biotherapy and Radiopharmaceuticals are committed to preserving the scientific literature and the community it serves and does not tolerate any violations of scientific misconduct. Therefore, the publisher officially retracts the article. [ABSTRACT FROM AUTHOR]

Effects of miR-34a expression on cell metastasis-associated protein expression in hepatocellular cells. **P<0.01 vs. control cells. miR, microRNA; miRSCR, scramble miR-34a; SIRT, sirtuin; p53, tumor protein 53, Ac-p53, acetylated p53. [Extracted from the article]

Cancer Biotherapy and Radiopharmaceuticals officially retracts the paper entitled, "LncRNA SNHG16 Promotes Proliferation, Migration, and Invasion of Glioma Cells Through Regulating the miR-490/PCBP2 Axis," by Fangen Kong, Yang Yan, Jinfeng Deng, Yaoli Zhu, Yingqin Li, Huiqing Li, and Yiping Wang (Cancer Biother Radiopharm. E-pub ahead of print 23 Jul 2020; doi: 10.1089/cbr.2019.3535) at the authors' request: "We apologized that we have found a serious problem in our paper. In fact, the Western blot experiment in our study was commissioned a third-party company for testing. In present, some peers have found that the company has forged experimental reports. After contacting the company, they were unable to provide the original images. We have checked and confirmed that the authenticity of the data provided by the company is problematic. In view of the problems in this paper, all the authors have discussed and agreed to withdraw the paper." [sic] The journal publisher requested the name of the "third-party company," to which the authors replied: "We apologize for our mistakes. Our so-called "the third party company", after further investigation, is actually not a company but an individual person. Due to the personal reasons, the previous experimental data were lost and the original raw data could not be provided. So we can not guarantee the authenticity of those data provided by that person. Some members are considering to repeat the experiment again, but we have no way to raise enough fund to repeat it. Hence after serious discussion, we decided to withdraw the manuscript. Again we apologize sincerely for your inconvenience." [sic] Submissions from a third party are a violation of the journal's standard protocols and is considered an infraction against the rigorous standards of scientific publishing. The Editor and Publisher of Cancer Biotherapy and Radiopharmaceuticals are committed to preserving the scientific literature and the community it serves and does not tolerate any violations of scientific misconduct. Therefore, the publisher officially retracts the article.